Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 1
Submit an article Journal homepage
45
Views
8
CrossRef citations to date
0
Altmetric
Miscellaneous

Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies-an update

Stephen Donoghue Elan Pharmaceuticals, Elan House, Avenue One, Letchworth, Herts, SG6 2HU, UK
&
Carol Greenlees Elan Pharmaceuticals, Elan House, Avenue One, Letchworth, Herts, SG6 2HU, UK
Pages 167-171 | Published online: 03 Mar 2005

Bibliography

  • EBERS GC, OGER J, PATY D et al: PRISMS (Prevention of Relapses and Disability by Interferon I3-la Subcutane-ously in Multiple Sclerosis) Study Group. Randomised double-blind, placebo-controlled study of interferon beta-la in relapsing-remitting multiple sclerosis. Lancet (1998) 352:1498–1504.
  • BLUMHARDT L: European Neurology Society 9th Meeting.June 5th-9th, Milan, Italy, (1999).
  • European Study Group on interferon beta-lb in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-lb in treatment of secondary progressive multiple sclerosis. Lancet (1998) 352(9139):1491–1497.
  • LEARY SM, MILLER DH, THOMPSON AJ: Design of a studyof interferon beta - la in primary progressive multiple sclerosis. J. Neurol. (1997) 244 (Suppl. 3) (Abstract) 563 :291.
  • SORENSEN PS, WANSCHER B, JENSEN CV et al.: Intrave-nous immunoglovulin G reduces MRI activity in relapsing multiple sclerosis. Neurology (1998) 50 (Suppl. 5):1273–1281.
  • ACHRION A, GABBAY U, GILAD R et al.: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology (1998) 50\(Suppl. 2)398–402.
  • ROMINE JS, SIPE JC, KOZIOL JA et al: A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians (1999) 111:35–44.
  • RICE G, THE CLADRIBINE STUDY GROUP: Effects ofcladribine on magnetic resonance imaging findings in progressive multiple sclerosis: Final results of a placebo-controlled trial. Ann. Neurol. (1998) 44:504.
  • HARTUNG HP, GONSETTE R AND THE MIMS-STUDYGROUP: mitoxantrone in progressive multiple sclerosis (MS): a placebo-controlled, randomized observer-blind European Phase III multicenter study-clinical results. Mull Scler. (1998) 4:325.
  • KRAPF H, MORRISSEY SP et al :Mitoxantrone in progres-sive multiple sclerosis (MS): a placebo-controlled, randomized, observer-blind European Phase III multicenter study-MRI results. Mult. Scler. (1998) 4:380.
  • TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect ofanti-a4 integrin antibody on brain lesion activity in MS. Neurology (1999) 53:466–472.
  • LUBLIN F: A Phase II trial of anti-CD11/CD18monoclonal antibody in acute exacerbations of multiple sclerosis. Neurology (1999) 52 (Suppl. 2):45.006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.